Tubulin in Medical Technology

CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma

... cancer and brain tumors. CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against GPNMB linked to a potent tubulin destabilizing agent, monomethyl auristatin E (MMAE). The enzyme-sensitive linker, which was licensed from Seattle Genetics, is designed to be stable ...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

... of the oncogenic transcription factor proteins HIF-1alpha, pSTAT3, and pNFkappaB. Treatment with ENMD-1198 also downregulates expression of several tubulin isotypes in 1A9 cells, but not in ENMD-1198-resistant (1A9-1198R) cells. This, combined with the relative lack of inhibition of oncogenic proteins ...

EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds

... The mechanisms of action of these three tubulin agents was compared and contrasted during ... highly dynamic filaments are composed of dimeric tubulin proteins. Microtubule targeting drugs are one ... antiproliferative and antiangiogenic properties. tubulin binding and subsequent microtubule disruption are ...

ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR

... peripheral neuropathy. While indibulin binds to tubulin in general, it does not bind to neuronal specific tubulin and does not disrupt normal axonal microtubules ... building blocks, tubulin. However, the specific tubulin binding site for indibulin is different from that ...

EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models

... Previous studies showed that ENMD-1420 inhibits tubulin polymerization and TNF-alpha production, ... stated, "We continue to make good progress on our tubulin inhibitor program. The results of these studies ... . About tubulin Inhibitors Tubulins are the proteins that form ...

EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers

... from MKC-1 binding to multiple intracellular targets, including tubulin and the importin-beta proteins. The importin-beta family of proteins plays ... cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. ...

Nereus Pharmaceuticals to Present Data at the American Association for Cancer Research 2007 Annual Meeting

... well as single-agent efficacy in a number of orthotopic models. NPI-2358 interacts with soluble beta-tubulin and prevents the polymerization of tubulin without altering dynamic microtubule function of formed microtubules. As demonstrated in pre-clinical testing, this target profile results in a ...

Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting

... in Pancreatic and Prostate Orthotopic Models of Cancer Poster Session: Angiogenesis Inhibitors Poster 3984: A Novel Class of tubulin Inhibitors that Exhibit Potent Antiproliferation and Vascular Targeting Activities Poster Session: Angiogenesis Inhibitors Poster ...

EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting

... as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's ...

Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials

... is the basis for which drugs are utilized in studies. The design of the protocol is (assuming the new agent is synergistic with an anthracycline, a tubulin interactive agent, an antimetabolite, or an angiogenesis inhibitor of an antibody to epidermal growth factor receptor, EGFR) patients with ...